Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms

被引:18
|
作者
Shimomura, Yutaro [1 ]
Kikuchi, Yuhei [1 ]
Suzuki, Takefumi [2 ]
Uchida, Hiroyuki [1 ]
Mimura, Masaru [1 ]
Takeuchi, Hiroyoshi [1 ]
机构
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[2] Univ Yamanashi, Fac Med, Dept Neuropsychiat, Yamanashi, Japan
关键词
Algorithms; Antipsychotics; Guidelines; Non-response; Schizophrenia; Treatment resistance; NAIVE 1ST-EPISODE SCHIZOPHRENIA; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED-TRIAL; CLOZAPINE; AUGMENTATION; METAANALYSIS; MANAGEMENT; DRUGS; SCALE; RISPERIDONE;
D O I
10.1016/j.schres.2021.07.040
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: To summarize the current state of knowledge on antipsychotic treatment strategies for the acute phase and treatment resistance in schizophrenia, we conducted a systematic review of guidelines and algorithms. Methods: We conducted a systematic literature search to identify clinical guidelines and algorithms on this topic using MEDLINE and Embase. We extracted information on recommendations for antipsychotic treatment strategies, including those for non-response (i.e., increasing antipsychotic dose and switching to another antipsychotic) and treatment resistance. Results: We identified a total of 17 guidelines/algorithms in various countries that were published after 2011. With respect to antipsychotic dose, most of the guidelines (N = 10/11) agreed starting with a low dose or the lowest licensed/effective dose and then titrating the dose upwards. Regarding antipsychotic treatment strategies for non-response, all of the guidelines (N = 9/9) recommended increasing antipsychotic dose towards the upper end of its approved dose range. Five guidelines suggested for increasing beyond the therapeutic dose range in exceptional cases, while overall 10 guidelines including them were negative about such strategy. The vast majority of guidelines (N = 16/17) recommended switching to another antipsychotic for non-response; however, some guidelines mentioned the lack of evidence for these strategies other than the use of clozapine. All the guidelines (N = 17/17) endorsed initiating clozapine after failure to respond to 2 different antipsychotics. Four guidelines endorsed an early use of clozapine, yet as the third antipsychotic. Conclusion: The currently available guidelines and algorithms recommended increasing antipsychotic dose and switching to another antipsychotic, particularly clozapine for treatment-resistant schizophrenia, during the acute phase of schizophrenia for non-response.
引用
收藏
页码:142 / 155
页数:14
相关论文
共 50 条
  • [31] Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy
    Hatta, Kotaro
    Sugiyama, Naoya
    Ito, Hiroto
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2018, 8 (06) : 173 - 183
  • [32] Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis
    Ceraso, Anna
    Lin, Jessie Jingxia
    Schneider-Thoma, Johannes
    Siafis, Spyridon
    Heres, Stephan
    Kissling, Werner
    Davis, John M.
    Leucht, Stefan
    SCHIZOPHRENIA BULLETIN, 2022, 48 (04) : 738 - 740
  • [33] Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis
    Vayisoglu, Sefa
    Karahan, Sevilay
    Anil Yagcioglu, A. Elif
    TURK PSIKIYATRI DERGISI, 2019, 30 (04) : 253 - 259
  • [34] Comparative Effectiveness of Amisulpride and Clozapine in the Treatment of Schizophrenia: A Systematic Review and Meta-Analysis
    Cedeno, Rommy
    Jaramillo, Arturo P.
    Khan, Ahmad R.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [35] Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Haya Ascher-Svanum
    Douglas E Faries
    Christoph U Correll
    John M Kane
    BMC Psychiatry, 8
  • [36] ACUTE TREATMENT OF SCHIZOPHRENIA: INTRODUCTION TO THE WORD FEDERATION OF SOCIETIES OF BIOLOGICAL PSYCHIATRY GUIDELINES
    Thibaut, Florence
    PSYCHIATRIA DANUBINA, 2014, 26 (01) : 2 - 11
  • [37] Role of Antipsychotic Polypharmacotherapy in the Treatment of Schizophrenia
    Patricia L. Canales
    Jerry Olsen
    Alexander L. Miller
    M. Lynn Crismon
    CNS Drugs, 1999, 12 : 179 - 188
  • [38] Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review
    Jakobsen, Klaus Damgaard
    Skyum, Eva
    Hashemi, Nasseh
    Schjerning, Ole
    Fink-Jensen, Anders
    Nielsen, Jimmi
    JOURNAL OF PSYCHOPHARMACOLOGY, 2017, 31 (04) : 397 - 405
  • [39] Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication Literature Review
    Vuk, Antonia
    Baretic, Maja
    Osvatic, Martina Matovinovic
    Filipcic, Igor
    Jovanovic, Nikolina
    Kuzman, Martina Rojnic
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (05) : 584 - 589
  • [40] Prediction of Response to Antipsychotic Drugs in Schizophrenia Patients within the Early Phase of Treatment
    Yildiz, Mesut
    Yazici, M. Kazim
    Yagcioglu, A. Elif Anil
    Karahan, Sevilay
    Sevik, Ali Emre
    Gurses, Nadide
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 25 (04): : 390 - 398